SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: James Baker who wrote (4128)12/31/1997 11:08:00 AM
From: Evan Dimmer  Read Replies (1) | Respond to of 23519
 
Huge volume AGAIN today. I cannot wait until next week!!!!!!!!

Ed



To: James Baker who wrote (4128)12/31/1997 11:12:00 AM
From: BigKNY3  Respond to of 23519
 
James Baker <<For the number of patients with ED in the population, 400 pt in 20 sites = only 20 pt per site. This seems like a tiny number for the quoted study>>

Using multiple sites makes this study even more impressive. It helps to minimize possible one-site bias. The # of patients per site was probably written into the protocol. Getting ED patients for these studies is not a problem.

BigKNY3



To: James Baker who wrote (4128)12/31/1997 2:20:00 PM
From: Cacaito  Respond to of 23519
 
I. Goldstein and Padma-Nathan will work together in the
Senetek US study. It was announced on the Spain conference about two
months ago, the press report can be found on prnewswire archives on
Senetek. They are going to conduct the phase III study on injection
combination of phentolamine and VIP. Please confirm it, this is just
from my memory.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News